The Codex4SMEs project, which has a €3.1 million budget, involves seven countries to increase cooperation in Europe's northwest region to develop companion diagnostics.
The funding will support various projects and research centers that are advancing precision medicine and genomic technology development.
Theradiag's Lisa Tracker monitoring kits will be referenced in supply contracts for Merck's immunosuppressant drug.
The companies will develop a platform for sample and workflow management, genetic data interpretation, and external client communication.
The companies will combine their respective technologies to develop epigenetic assays for cancer patient stratification and personalized treatment.
The company will use the money to bring its Elsie genomic information platform to markets internationally.
Philips and its partners aim to combine liquid biopsy with magnetic resonance imaging to enable personalized cancer treatment.
Konica Minolta paid $800 million up front for Ambry, with Ambry shareholders eligible to receive up to $200 million in future payments.
The firm's CEO said that its assay is applicable in other indications where immunosuppressive therapies are used, such as rheumatoid arthritis.
The company hopes to build enrollment of men with advanced prostate cancer within its larger Strata Trial — which provides free targeted sequencing and tracks its impact on clinical trial enrollment.